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Abstract
Using a modified version of the mRNA differential
display technique, five human bladder cancer cell lines
from low grade to metastatic were analyzed to identify
differences in gene expression. A 316-bp cDNA (C11-
300) was isolated that was not expressed in the
metastatic cell line TccSuP. Sequence analysis revealed
that this gene was identical to KIAA 0429, has a 5.3-kb
transcript that mapped to 8q24.1. The protein is
predicted to be 356 amino acids in size and has an
actin -binding WH2 domain. Northern blot revealed
expression in multiple normal tissues, but none in a
metastatic breast cancer cell line (SKBR3) or in
metastatic prostatic cancer cell lines (LNCaP, PC3).
We have named this gene Missing in Metastasis (MIM )
and our data suggest that it may be involved in
cytoskeletal organization.
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Introduction
Bladder cancer is the second most common cancer of the
genitourinary tract in the United States. Approximately 30%
to 70% of superficial bladder tumors will recur after initial
treatment and 10% to 30% will progress to invasive and/or
metastatic disease [1]. It is likely that this progression is the
result of genetic changes that transform a superficial cancer
to one with metastatic potential, including activation of
oncogenes or loss of tumor suppressor genes [2]. The
objective of this study was to identify differentially expressed
genes related to the progression and metastasis of transi-
tional cell bladder cancer utilizing a modified, nonradioactive
differential display technique [3].
Materials and Methods
RNA Isolation
Total RNA was isolated using TRIzol reagent (Life
Technologies, Grand Island, NY), and purified by digestion
with RNAse- free DNAse I from the following cell lines: RT4, a
bladder papilloma cell line; 5637, a bladder superficial transi-
tional cell cancer cell line; HT1376, a bladder invasive
transitional cell cancer cell line; T24, a bladder invasive
transitional cell cancer cell line; TccSuP, a metastatic bladder
transitional cell cancer cell line; MCF7, a human breast cancer
cell line; MCF10A, a benign breast fibroadenoma cell line;
SKBr3, a metastatic breast cancer cell line; PrEC-1, a human
prostate cell line; andmetastatic prostate cancer cell linesPC-
3, TSU-PR1, DU145; and LNCaP. All cell lines were obtained
from the American Type Culture Collection (Manassas, VA)
except PrEC-1 cells that were obtained from Clonetics (East
Rutherford, NJ). mRNA was isolated from total RNA using
PolyA-Ttract mRNA Isolation Systems (Promega, Madison,
WI) according to the manufacturer’s recommendations.
Reverse Transcription of RNA
DEPC H2O was added to 2 to 5 g of poly A
+ RNA per
sample to bring the total volume to 22 l. The RNA was
heated at 658C for 5 minutes and then placed on ice. Master
mix containing 8 l of 5 reverse transcription buffer, 4 l of
0.1 M DTT, 2 l of 10 mM dNTP, 2 l of random hexamers
(50 ng/l ) and 2 l of MML-V reverse transcriptase (200 U/
l was added per tube containing denatured RNA, then
incubated as follows: 228C for 10 minutes, 378C for
50 minutes, 708C for 15 minutes and then 48C.
Amplification of cDNA
Reverse- transcribed RNA (cDNA) was amplified in
separate polymerase chain reactions (PCR) using 40
random 10-mers at 5 M per reaction (Operon, Alameda,
CA). Master mix containing 3 l of 10PCR buffer, 0.3 l of
10 mM dNTPs, 0.9 l of 50 mM MgCl2, 0.2 l Taq DNA
polymerase (5U/l ) and 20.6 l of sterile dH2O was added
into 2 l of cDNA and 3 l of random primer. The cycling
parameters using Perkin-Elmer 9600 thermocycler (Perkin-
Elmer, Shelton, CT) were as follows: 948C, 2 minutes at first
cycle; 948C, 45 seconds; 388C 2 minutes; 728C, 1 minute 15
seconds for 40 cycles followed by 728C 15 minutes and then
48C soaked. The PCR products were separated on 2%
agarose (DNA typing agarose, Gibco BRL, Grand Island,
NY) and visualized with 0.3 g/ml ethidium bromide staining
under UV light. Differentially expressed bands were excised
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from the agarose gel using a scalpel and extracted using a
Qiaex gel extraction kit (Qiagen, Valencia, CA) [3,6 ].
Cloning and Sequencing of cDNAs
cDNAs were purified utilizing the High Pure PCR product
purification kit (Boehringer Mannheim, Indianapolis, IN),
cloned into a plasmid TA cloning vector, pGEM-T easy
(Promega) and sequenced using the T7 and/or the SP6
primer. Sequences were blasted against Genbank.
Northern Blot Analysis
Two micrograms of poly A+ RNA was denatured and
electrophoresed through a 1.2% denatured agarose/ form-
aldehyde gel and transferred to nylon membrane (Scleicher
& Schuell, Keene, NH). The membrane was cross- linked by
a UV Stratalinker and dried under vacuum for 2 hours, then
prehybridized with 20 ml of the hybridization solution (50%
formamide, 5 SSC, 1 PE, and 125 g/ml of denatured
sheared salmon sperm DNA) for 2 to 8 hours. The human
multiple tissue Northern blot membrane was purchased from
Clontech (Palo Alto, CA). All probes were random labeled
with 32PdCTP using an Oligolabeling kit (Pharmacia
Biotech, Piscataway, NJ). Hybridization was performed for
16 hours at 428C, then the membrane was washed under
stringent conditions: twice for 10 minutes in 2 SSC plus
0.1% sodium pyrophosphate plus 0.1% SDS at 658C, once
for 10 minutes and 30 minutes in 0.2 SSC plus 0.1%
sodium pyrophosphate plus 0.1% SDS at 658C, respectively.
Autoradiography was performed using Kodak XAR film
(Kodak, New Haven, CT) at 808C. After removal of cDNA
probesbywashing in 1008CH2O for 10minutes, the sameblot
was rehybridized with human tubulin or -actin as controls.
Chromosomal Mapping
Chromosomal mapping was obtained using the BLAST
algorithm with the C11-300 sequence against the Human
Genome sequence database through the National Center for
Biotechnology website as accessed through the Internet
(http://www.ncbi.nlm.nih.gov/ ).
Protein Homology Search and Protein Profile Scan
The predicted 356- residue MIM protein sequence was
examined for the presence of functional motifs through a
ProfileScan search of the protein profile entries in PROSITE,
Pfam and MultAlin accessed through the ExPASy (Expert
Protein Analysis System) proteomics server of the Swiss
Institute of Bioinformatics (SIB) (http://www.expasy.ch).
Results and Discussion
We have modified the original differential display technique
developed by Liang and Pardee by utilizing a 50 random
decamer and 2% DNA typing agarose with visualization after
ethidium bromide staining [3,4 ]. Using this technique, a 300-
bp amplicon, C11-300, was amplified from RNA using the
random primer 50 AAAGCTGCGG 30 in the RT4, 5637,
HT1376 T24, but not the TccSuP cells TccSup (Figure 1 ).
Because this gene was not expressed in metastatic bladder
cells we have termed it Missing in Metastasis (MIM ). The
amplicon was cloned and used as a probe in Northern
blot analysis. The differential expression pattern of MIM
was confirmed for RT4, 5637, HT1376, T24 and TccSuP
cells by Northern blot analysis (Figure 2A ). TccSuP cells
were derived from an anaplastic transitional cell carci-
noma from a patient with metastases to the bone. A
human normal multiple tissue Northern blot demonstrated
that MIM was expressed in many tissues including spleen,
thymus, prostate, testis, uterus, colon, and peripheral
blood (Figure 2B ). In addition to the 5.3-kb major
transcript, testis expresses a 2.0-kb transcript. Northern
blot analysis in breast cell lines showed that MIM was not
expressed in the SkBr3, a metastatic breast cancer cell
line, but was expressed in MCF10A, a benign breast
fibroadenoma cell line, and MCF7, a breast cancer cell
line derived from pleural fluid (Figure 2C ). Northern blot
analysis in prostate cell lines demonstrated MIM was not
expressed in PC-3 and LNCaP, metastatic prostate
cancer cell lines, but was minimally expressed in PrEC-1,
a prostate epithelial cell line, and DU145, a metastatic
prostate cancer cell line (Figure 2D ). The transcript was
expressed in TSU-PR1, a presumably metastatic prostate
cancer cell line. Interestingly, a recent report suggests that
TSU-PR1 may be a transitional cell cancer cell line derived
from the bladder tumor cell line T24 [5]. The transcript is
present in the T24 cell line (Figure 2A ). These results
suggest that MIM may be related to cancer progression or
tumor metastasis in a variety of organ sites.
The amplicon was cloned and sequenced and found to be
100% homologous to the 5645-bp KIAA0429 gene transcript
(GenBank accession # NM_014751). BLAST analysis of the
C11-300 amplicon sequence against the Human Genome
sequence database showed that it localized to contig
NT_023726 and maps to chromosomal region 8q24.1. The
NM-014751 nucleotide sequence contains a 1068 nt open-
reading frame that encodes a 38-kDa protein 356 amino acid
residues in length (Figure 3 ).
A protein homology search demonstrates that MIM has a
proline- rich region and a W Wiskott -Aldrich syndrome
protein (WASp) Homology 2 (WH2) motif (Figure 3 ) [6,7 ].
The WH-2 motif participates in actin monomer binding. The
WASp family of proteins is thought to help initiate the growth
Figure 1. The 316 -bp cDNA is not expressed in TccSup (Lane 6 ) by PCR.
Lane 1: 100 -bp DNA marker. Lane 2: RT4 (bladder papilloma cell line ). Lane
3: 5637 (bladder superficial transitional cell line ). Lane 4: HT 1376 (bladder
invasive TCC cell line ). Lane 5: T24 (bladder invasive TCC cell line ). Lane 6:
TccSup (metastatic bladder TCC cell line ).
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of a new actin filament on the side of an existing one [6].
Their activity is regulated by the Rho- family GTPases and
these interactions are thought to provide a final common
signaling pathway for actin polymerization [6].
The mammalian WASp/Scar family currently consists of
five members: WASp, N-WASP, and three Scar (suppres-
sor of cAMP receptor ) isoforms [7]. The gene encoding
WASp is mutated in Wiskott -Aldrich syndrome, an X- linked
human disease with selective defects in platelet development
and lymphocytes. WASp has a binding motif for activated
Cdc42 and Rac, suggesting that WASp might regulate
actin, because these Rho family GTPases influence actin
Figure 2. Northern blot analysis of cell lines and tissues utilizing the C11 300 cDNA as a probe. A. Bladder cancer cell lines. B. Normal tissues. C. Breast cancer cell
lines. D. Prostate cancer cell lines.
Figure 3. The protein sequence for MIM. The predicted protein sequence is 356 bp. The proline - rich region stretches from bp 209 to 284 (bold italicized ). The WH2
domain encompasses the bp region 328 to 345 (bold underlined ).
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dynamics, and because transfection of WASp rearranges
actin filaments in cultured cells [7 ]. N-WASP, originally
described in neural cells, is expressed more widely in
vertebrate cells than WASp and causes filopodial formation.
Scar was discovered in Dictyostelium and deletion causes
cytoskeletal defects. G-protein-coupled receptors trigger
the reorganization of the actin cytoskeleton in many cell
types. Scar cells have reduced levels of F-actin staining, and
abnormal cell morphology and actin distribution during
chemotaxis.
Our data suggest that MIM may be lost in certain cells
that express a metastatic phenotype. Actin filament
assembly is associated with cytoskeletal structure organi-
zation and many forms of cell motility. Alteration of actin
assembly /disassembly dynamics may have serious conse-
quences on the ability of cells tometastasize.MIM appears to
be an exciting new gene product that may be involved in
invasion and metastasis, most likely through an interaction
with the actin cytoskeleton. Work is underway to characterize
its exact role in regulation of the cytoskeleton and to further
describe its distribution in normal tissueaswell as primary and
metastatic tumors.
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